Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2026-04-28 Remuneration Information
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
关于2026年度公司董事、高级管理人员薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the 2026 remuneration scheme for the company's directors and senior management. It details the salary structure, payment terms, and approval procedures for the board and senior executives. The content focuses exclusively on compensation policies and related governance matters. There is no financial performance data, audit information, or report publication mentioned. The document aligns with the definition of Remuneration Information filings, which detail compensation for top executives and directors. The document length is 1807 characters, which is consistent with a detailed announcement rather than a full annual report or other financial filings.
2026-04-28 Chinese
关于公司未弥补亏损达到实收股本总额三分之一的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement by Beijing Kangle Weishi Biotechnology Co., Ltd. regarding the company's accumulated losses reaching one-third of its paid-in capital. It includes audited financial figures as of December 31, 2025, and discusses the company's financial condition, reasons for losses, and planned measures. The document references a board meeting resolution and is a formal disclosure to shareholders and the public about the company's financial status and related corporate governance matters. It is not a full annual report or interim report but a specific regulatory announcement about financial distress and board decisions. This fits best under Regulatory Filings (RNS), as it is a regulatory announcement that does not fit other specific categories like Annual Report or Management Reports.
2026-04-28 Chinese
2025年度独立董事述职报告（乔友林）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 by an independent director of the company. It details the director's background, attendance at board and committee meetings, exercise of duties, communication with shareholders, and other governance-related activities during the year. It also discusses changes in senior management and audit firm appointments. The content focuses on the independent director's duties and governance oversight rather than financial results or audit opinions. This type of document is a report by a board member on their management and governance activities, which fits best under the category of Board/Management Information (MANG). The document length is over 5,000 characters and contains substantive content, so it is not a mere announcement. Therefore, the classification is MANG with high confidence.
2026-04-28 Chinese
关于累计诉讼、仲裁的公告
Legal Proceedings Report Classification · 95% confidence The document is an announcement from Beijing Kangle Weishi Biotechnology Co., Ltd. regarding cumulative litigation and arbitration cases involving the company and its subsidiaries. It details the amounts involved, types of disputes, and the impact on the company's profits. The document references compliance with the Beijing Stock Exchange listing rules and provides legal case details but does not contain financial statements or detailed financial performance data. It is a regulatory disclosure about legal proceedings rather than a full legal report or financial report. Given the content and nature, this fits best under Legal Proceedings Report (LTR). The document length is short and focused on legal matters, not a full audit or annual report, nor a simple announcement of a report publication.
2026-04-28 Chinese
2025年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' (Audit Report) and contains detailed audit opinions, including a reserved opinion, key audit matters, management and auditor responsibilities, and extensive financial statements such as consolidated balance sheets, income statements, cash flow statements, and equity changes for the fiscal year ending December 31, 2025. The presence of an auditor's opinion, audit procedures, and detailed financial data confirms this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters), and it includes the auditor's signature and date, consistent with an audit report. Therefore, the document fits the category of Audit Report / Information (AR). FY 2025
2026-04-28 Chinese
2025年度营业收入扣除情况表的专项核查报告
Audit Report / Information Classification · 95% confidence The document is a specialized audit report titled "专项核查报告" (Special Audit Report) concerning the 2025 fiscal year revenue deduction schedule of Beijing Kangle Weishi Biotechnology Co., Ltd. It is issued by a certified public accounting firm and includes detailed audit procedures and conclusions about the revenue deduction schedule. The document references the 2025 financial statements but is not the full annual report itself. It is a standalone audit verification report focusing on a specific aspect of the financials (revenue deductions). The length is over 6,000 characters, indicating it is a full report, not a brief announcement. This fits the definition of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or other categories. Therefore, the correct classification is AR with high confidence. FY 2025
2026-04-28 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.